Slope Launches Tech-Enabled Services to Bolster Biospecimen Lifecycle Management in Clinical Trials

New tech-enabled services empower pharmaceutical companies to optimize biospecimen operations and data management, transforming sample data into actionable insights

RICHMOND, Va., Sept. 10, 2024 /PRNewswire/ — Slope, a global provider of biospecimen lifecycle software, data, and services for clinical trials, today announced the launch of a premium suite of services designed to empower clinical trial sponsors to harness the full potential of their biospecimen data from study startup to closeout.

Slope’s services empower clinical trial sponsors to harness the full potential of their biospecimen data.

“Our sponsor customers of Slope’s biospecimen lifecycle software, Biospecimen360™, already receive guidance from our team of experts along every touchpoint of the biospecimen lifecycle,” said Mark Melton, VP of Biospecimen Data and Operations at Slope. “Our new tech-enabled services elevate this support, ensuring our sponsors are actualizing the immense value of their sample data.”

Slope’s new Professional Services are a premium, customizable set of offerings that extend beyond the setup, execution, and optimization support offered to every customer. Collectively, Slope’s services support the following functions:

  • Lab & Biospecimen Operations: Slope provides deep expertise in protocol design, vendor selection, and sample collection workflows. By offering strategic guidance and operational oversight, these services help streamline trial execution, maintain quality standards, and meet critical timelines.
  • End-to-End Sample Tracking: Slope delivers robust monitoring and reconciliation of biospecimen movement and metadata. These services ensure accurate, real-time tracking throughout the biospecimen lifecycle, minimizing deviations and safeguarding sample integrity.
  • Biospecimen Data Management: From study setup to final database lock, Slope oversees all aspects of sample metadata. These services ensure rigorous data governance, data integrity, seamless data transfers, and streamlined reconciliation processes — all of which are essential for ensuring protocol endpoints are hit.

“We recognize the profound impact of controlling kit inventory, sample collection, processing, and shipment in a single platform on all stakeholders involved in a clinical trial,” added Melton. “With Slope’s new suite of services, you don’t just get quicker access to more high-quality data — you get the expertise to optimize your data and transform that data into actionable insights — driving better decisions and more efficient trials.”

Slope’s tech-enabled services provide a cost-effective, high-impact solution for pharmaceutical companies facing the challenges of complex, sample-intensive trials. By combining Biospecimen360™ with expert support, Slope empowers sponsors to unlock the full potential of their biospecimen data, ensuring that every decision is informed by real-time, high-quality information.

For more information, visit slopeclinical.com.

About Slope

Slope is a global provider of biospecimen lifecycle software, data, and services for clinical trials. With a focus on tech-enabling the full biospecimen lifecycle, Slope offers expertise that empowers sponsors to make informed decisions using high-quality, real-time sample data. Slope has supported thousands of the most complex, sample-intensive trials worldwide and has been adopted by nearly 80% of NCI-designated cancer centers. For more information, visit slopeclinical.com.

Media Contact
Fay Li
Praxcomm Strategies for Slope
fay@praxcomm.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/slope-launches-tech-enabled-services-to-bolster-biospecimen-lifecycle-management-in-clinical-trials-302242764.html

SOURCE Slope

Staff

Recent Posts

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

Media ReleaseCOPENHAGEN, Denmark; September 15, 2024 Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate…

6 hours ago

Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis

Trial investigating Cabometyx® (cabozantinib) in combination with atezolizumab demonstrated a positive trend towards improvement for…

6 hours ago

KFSHRC Leads as a Premier Destination for Medical Tourism and Innovative Care Solutions

RIYADH, Saudi Arabia, Sept. 15, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research…

6 hours ago

Precede Biosciences Presents New Data at ESMO 2024 Demonstrating Ability to Reveal Tumor PSMA Expression from a Simple Blood Test that is Highly Correlated with PSMA-PET Imaging

Prostate-specific membrane antigen (PSMA) is a leading target for next-generation prostate cancer therapies, with one…

6 hours ago

23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study

23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed…

6 hours ago